Shine-On BioMedical Co (ROCO:6926) Total Equity: NT$907.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6926 Shine-On BioMedical Co Ltd ROCO:6926
12 GF Score
Price NT$64.80
! 1 Warning Sign
View Full Analysis

What is Shine-On BioMedical Co Total Equity?

Shine-On BioMedical Co ROCO:6926 12 Total Equity is NT$907.28 Mil as of Dec. 2025. GuruFocus rates ROCO:6926 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Shine-On BioMedical Co's total equity for the quarter that ended in Dec. 2025 was NT$907.28 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Shine-On BioMedical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Shine-On BioMedical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shine-On BioMedical Co Total Equity Chart

Shine-On BioMedical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 907.57 1,173.63 1,136.46 1,017.57 907.28

Shine-On BioMedical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,136.46 1,090.00 1,017.57 972.93 907.28
ROCO:6926
12GF Score
Shine-On BioMedical Co Ltd ROCO:6926
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shine-On BioMedical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Shine-On BioMedical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=950.942-43.66
=907.28

Shine-On BioMedical Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=950.942-43.66
=907.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$907.28 Mil mean?
Shine-On BioMedical Co (ROCO:6926) has a Total Equity of NT$907.28 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Shine-On BioMedical Co and its competitors.
Is Shine-On BioMedical Co's Total Equity too high?
Shine-On BioMedical Co's current Total Equity is NT$907.28 Mil. Overall, Shine-On BioMedical Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Shine-On BioMedical Co's Total Equity compare to VRTX and REGN?
Shine-On BioMedical Co's Total Equity of NT$907.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Shine-On BioMedical Co and its competitors. Shine-On BioMedical Co's current Total Equity is NT$907.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shine-On BioMedical Co stock overvalued right now?
Shine-On BioMedical Co (ROCO:6926) has a current Total Equity of NT$907.28 Mil. The current Total Equity is NT$907.28 Mil. Shine-On BioMedical Co's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Shine-On BioMedical Co (ROCO:6926), the current Total Equity is NT$907.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shine-On BioMedical Co Business Description

Address No. 573, Taiwan Boulevard, 10th Floor, Section 2, West District, Taichung, TWN
Shine-On BioMedical Co Ltd develops drugs based on antibodies and nucleic acids. The Company researches, develops, manufactures, and distributes antibody anticancer drugs, nucleic acid anticancer drugs. The company's drug development and nucleic acid therapeutics are focused on providing patients with effective cancer treatment options.
12GF Score

Get the complete analysis for ROCO:6926

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$64.80
Price